持续抗击骨质疏松只需每年一次-唑来膦酸

In recent years, with the intensification of aging, the incidence of osteoporosis has gradually increased, which is also one of the main factors leading to the occurrence of osteoporotic vertebral compression fractures, seriously affecting the quality of life and physical and mental health of the elderly, and causing a serious economic burden to patients. Drug therapy is the main treatment for osteoporosis. It is a bisphosphonate drug that can effectively delay bone resorption, inhibit the activity of osteoclasts, and restore the dynamic balance of osteogenesis and osteoclasts. Bisphosphonates can relieve pain and delay collapse in the treatment of femoral head necrosis. Most importantly, the use of zoledronic acid to fight osteoporosis and other diseases only needs to be used once a year.

Taking zoledronic acid can affect the mevalonate pathway, and then inhibit the formation of osteoclasts, prevent the continued growth of osteoclasts, achieve a balance between bone absorption and formation, and then achieve the purpose of increasing bone density and bone mass, and better avoid the occurrence of fractures. This study found that in the treatment of severe osteoporosis in the elderly, the treatment method of calcium carbonate D3 + zoledronic acid can effectively treat bone pain in patients.

Zoledronic acid is currently the most pharmacologically active bisphosphonate drug. Compared with similar drugs, it has a stronger ability to bind hydroxyapatite. Zoledronic acid only needs to be administered once a year and is more convenient to use.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.